| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.
|
Am J Psychiatry
|
2011
|
9.18
|
|
2
|
The clinical global impressions scale: applying a research tool in clinical practice.
|
Psychiatry (Edgmont)
|
2007
|
3.02
|
|
3
|
Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology.
|
Neurology
|
2014
|
2.37
|
|
4
|
Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center.
|
J Gen Intern Med
|
2008
|
2.08
|
|
5
|
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
|
Lancet Neurol
|
2015
|
2.07
|
|
6
|
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
|
Epilepsia
|
2014
|
1.97
|
|
7
|
Development of the quality of life in epilepsy inventory.
|
Epilepsia
|
1995
|
1.93
|
|
8
|
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
|
Braz J Med Biol Res
|
2006
|
1.76
|
|
9
|
History of cannabis and its preparations in saga, science, and sobriquet.
|
Chem Biodivers
|
2007
|
1.60
|
|
10
|
Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.
|
Epilepsy Behav
|
2013
|
1.50
|
|
11
|
Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women.
|
Clin Pharmacol Ther
|
1983
|
1.44
|
|
12
|
Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking.
|
Clin Pharmacol Ther
|
1980
|
1.43
|
|
13
|
Adverse health effects of marijuana use.
|
N Engl J Med
|
2014
|
1.37
|
|
14
|
The case for medical marijuana in epilepsy.
|
Epilepsia
|
2014
|
1.28
|
|
15
|
Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy.
|
Epilepsy Behav
|
2015
|
1.13
|
|
16
|
Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.
|
J Pharmacol Exp Ther
|
2009
|
1.12
|
|
17
|
Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.
|
Epilepsia
|
2015
|
1.07
|
|
18
|
Age at onset of epilepsy, pharmacoresistance, and cognitive outcomes: a prospective cohort study.
|
Neurology
|
2012
|
1.06
|
|
19
|
Safety and side effects of cannabidiol, a Cannabis sativa constituent.
|
Curr Drug Saf
|
2011
|
1.03
|
|
20
|
Cannabinoids for epilepsy.
|
Cochrane Database Syst Rev
|
2012
|
1.01
|
|
21
|
The case for assessing cannabidiol in epilepsy.
|
Epilepsia
|
2014
|
0.96
|
|
22
|
Letter: The effect of cannabidiol on maximal electroshock seizures in rats.
|
J Pharm Pharmacol
|
1973
|
0.86
|
|
23
|
Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.
|
Epilepsia
|
2016
|
0.86
|
|
24
|
The Pharmacological Basis of Cannabis Therapy for Epilepsy.
|
J Pharmacol Exp Ther
|
2016
|
0.85
|
|
25
|
Placebo and nocebo responses in drug trials of epilepsy.
|
Epilepsy Behav
|
2015
|
0.85
|
|
26
|
CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.
|
Seizure
|
2016
|
0.84
|
|
27
|
Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature.
|
Rev Neurol Dis
|
2007
|
0.80
|
|
28
|
Opportunity gained, opportunity lost: treating pharmacoresistant epilepsy in children.
|
Epilepsia
|
2013
|
0.78
|
|
29
|
Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol.
|
Biochem Pharmacol
|
1994
|
0.77
|
|
30
|
Potential therapeutical effects of cannabidiol in children with pharmacoresistant epilepsy.
|
Med Hypotheses
|
2006
|
0.77
|
|
31
|
Cannabinoids in paediatric neurology.
|
Dev Med Child Neurol
|
2015
|
0.75
|
|
32
|
Options for pharmacoresistant epilepsy in children: when medications don't work.
|
Pediatr Ann
|
2015
|
0.75
|
|
33
|
Investigational new drugs for focal epilepsy.
|
Expert Opin Investig Drugs
|
2015
|
0.75
|
|
34
|
Development and assessment of a shortened Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55).
|
Epilepsia
|
2015
|
0.75
|
|
35
|
Interaction of delta9-tetrahydrocannabinol and cannabidiol with phenobarbitone in protecting mice from electrically induced convulsions.
|
J Pharm Pharmacol
|
1975
|
0.75
|
|
36
|
Validating the shortened Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55) in a sample of children with drug-resistant epilepsy.
|
Epilepsia
|
2017
|
0.75
|